Dendreon Corp fka DNDNQ

[mouton29]

<<1/3 is very optimistic. I am one who believs in the efficacy of Provenge but seriously doubt the interum peek hits.>>

I am curious how you reconcile the belief in the efficacy of Provenge, combined with the statement by Dr.Gold that the interim analysis is "very well powered" - not merely "well powered" -- with concluding that the chance of a successful interim look is much less than 1/3rd. From the transcript portion quoted in post 3795

Gold: What we said Charles is that on the final analysis is planned at 360 death events—it’s a 500 patient target enrollment study—the study is more than 90% powered. The interim analysis that is planned is very well powered but we’re not going to get into the specifics on the interim: